维普期刊资源整合服务平台（V6.5）

340篇 您的检索式：作者名="Davidson MH"

选中清除导出查看参考文献查看引证文献引用追踪共17页首页上一页第1页下一页末页 /17 跳转

	题名	作者	年代	出处	被引量
1	Safety of aggressive lipid management 显示文摘	Davidson MH Robinson JG	2007	J Am Coil Cardiol2007，49，17：	1
2	Ezetimibe coadministered with simvastatin In patients with primary hypercholesterolemia显示文摘	DAVIDSON MH MCGARRY T BETTIS R	2002	J Am Coll Cardiol2002，40，12：	1
3	Rosuvastatin safety: lessons from the FDA review and post-approval surveillance显示文摘	DAVIDSON MH	2004	Expert Opin Drug Saf2004，3，6：	1
4	Reduction of LDL cholesterol by 25%-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor 显示文摘	Nawrocld JW Weiss SR Davidson MH	1995	Artefioscler Thromb Vasc Biol1995，15，2：	1
5	Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force显示文摘	McKenney JM Davidson MH Jacobso TA		0，，8：	1
6	Clinical significance of statin pleiotroic effects hypotheses versus evidence 显示文摘	Davidson MH	2005	Circulation2005，111，18：	1
7	Cardiovascular effects of glucagonlike pep- tide-1 agonists 显示文摘	Davidson MH	2011	Am J Cardiol2011，108，：	1
8	Clinical significance of statin pleiotroiceffects h- ypotheses versus evidence显示文摘	Davidson MH	2009	Circulation2009，，9：	1
9	Efficacy and safety of torcetrapib,a novel cholesteryl ester transfer protein inhibitor,in individuals with below-average high-density lipoprotein cholesterol levels显示文摘	Davidson MH Mckenney JM Shear CL	2006	J Am Coll Cardiol2006，48，9：	1
10	Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial 显示文摘	Hauptman J DiGirolamo M	1999	JAMA1999，281，：	1
11	Safety of aggressive lipid management显示文摘	Davidson MH Robinson JG	2007	J Am Coll Cardiol2007，49，17：	1
12	Low high-density lipo-protein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials 显示文摘	Deedwania P Singh V Davidson MH	2009	Am J Cardio2009，104，10：	1
13	Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study) 显示文摘	Bays HE Davidson MH Massad R	2011	Am J Cardiol2011，108，4：	1
14	Efficacy and safety of torcetrapib,a novel cholesteryl ester transfer protein inhibitor,in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin显示文摘	Mckenney JM Davidson MH Shear CL	2006	J Am Coll Cardiol2006，48，9：	1
15	Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia 显示文摘	DAVIDSON MH	2002	Expert Opin lnvestig Drugs2002，11，3：	1
16	Efficacy and safety of a new HMG-coA reductase inhibitor,atorvastatin,in patients with hypertriglyceridemia显示文摘	Bakkev-Arkema RG Davidson MH Goldstein RT	1996	Jam Med Assoc1996，275，2：	1
17	Updating the assessment of cardiac risk: beyond Framingham 显示文摘	Borden WB Davidson MH	2009	Rev cardiovase Med2009，10，2：	1
18	Comparison of the effica-cy and safety of rosuvastatin versus atorvastatin,sinvastatin,andpravastatin acrossdoses(STELLAR Trial)显示文摘	Jones PH Davidson MH Stein EA	2003	Am J Cardial2003，92，2：	1
19	Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia显示文摘	Davidson MH McGarry T Bettis R	2002	J Am Coll Cardiol2002，40，12：	1
20	Ezetimibe coadministrated with simvastatin in patients with primary hypercholesterolemia显示文摘	Davidson MH McGarryT Bettis R	2002	JA CC2002，40，12：	1

返回顶部每页显示：

共17页首页上一页第1页下一页末页 /17 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示